The global 16S rRNA and amplicon sequencing market was valued at USD 2.12 billion in 2025. It is estimated at USD 2.33 billion in 2026 and is projected to reach USD 5.46 billion by 2036, at a CAGR of 8.9% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering microbiome research, clinical oncology and inherited disease panels, pathogen surveillance, long-read marker gene sequencing, regulatory approvals, pricing and cost per sample, the supplier landscape, and future growth opportunities.
The market covers the reagents, sequencers, software, and services that laboratories use to copy and then sequence chosen stretches of DNA or RNA. Amplicon methods use PCR to enrich target regions before sequencing, which keeps costs low, works with small amounts of input, and supports detection of low-frequency variants. Uses in scope include 16S rRNA gene and internal transcribed spacer (ITS) sequencing to profile bacteria and fungi, human gene panels for cancer hotspot mutations, inherited disease, and pharmacogenomics, tiled and targeted panels for viral genomes and drug resistance, genotyping for crop and livestock breeding and food checks, and confirmation of gene editing outcomes. Shotgun metagenomics, hybrid capture-based targeted sequencing, whole-genome and whole-exome sequencing, and PCR or qPCR assays without a sequencing readout are excluded.
Thermo Fisher Scientific's Oncomine Dx Express Test, approved in July 2025 by the Food and Drug Administration (FDA), is an amplicon test that covers 46 genes, runs on the Genexus Dx Integrated Sequencer, can return results within about a day, and serves as a companion diagnostic for sunvozertinib in EGFR exon 20 insertion non-small cell lung cancer and for solid tumor profiling. The FDA has also granted premarket approval to Pillar Biosciences' oncoReveal Dx Lung and Colon Cancer Assay. In microbiome testing, Microba Life Sciences reported a 78% rise in core testing volume to 22,418 tests in fiscal year 2026.
Shotgun metagenomics, hybrid capture panels, and whole-genome sequencing are becoming cheaper and provide wider information, such as strain-level and functional microbial data or copy number changes and new fusions, which pulls some work away from amplicon methods. PCR bias, primer mismatches, chimeras, and differences in gene copy number between organisms can distort results, and short-read sequencing of 16S variable regions often cannot separate closely related species. Microbiome workflows also lack common choices of variable regions, primers, extraction methods, and pipelines, which makes studies hard to compare, while panels must be redesigned as clinical biomarkers change and viruses mutate in primer binding sites.
Reading the complete 16S and ITS regions on long-read instruments is a significant opportunity, as reading the whole gene raises taxonomic resolution to species and sometimes strain level while keeping amplicon economics; Oxford Nanopore Technologies launched its Microbial Amplicon Barcoding Kit 24 V14 in September 2025 with a library ready about one hour after PCR. Rapid in-house clinical NGS, verification of CRISPR edits in cell and gene therapy manufacturing, and agricultural genotyping, food authenticity, and environmental DNA testing offer further openings. Key trends include the shift to full-length and long-read amplicon sequencing, automated sample-to-result workflows, and combined DNA and RNA or multi-pathogen panels.
By offering, the 16S rRNA and amplicon sequencing market is segmented into kits & reagents (amplicon panels & primers, library preparation kits, and other reagents), instruments, software & bioinformatics, and services. Kits & reagents are expected to hold the largest share in 2026, because panels, primers, and library preparation kits are consumed in every experiment and clinical test, and a broad base of installed sequencers of both read types keeps demand recurring. Services are set to record the highest CAGR, as large microbiome studies are outsourced to sequencing providers, clinical microbiome and oncology testing services expand, and cell and gene therapy developers buy editing verification work. Software & bioinformatics is expected to grow strongly on the need for standard microbiome pipelines and automated clinical reports, while instruments benefit from the uptake of integrated benchtop sequencers in hospitals.
By target type, the 16S rRNA and amplicon sequencing market is segmented into human targeted gene panels, 16S rRNA & ITS microbial marker gene sequencing, pathogen genome & resistance amplicon sequencing, plant & animal genotyping amplicons, and other targets. In 2026, human targeted gene panels, which include oncology, inherited disease, and pharmacogenomic panels, are expected to lead, driven by wide use of amplicon oncology panels for treatment selection, FDA-approved amplicon tests from Thermo Fisher Scientific and Pillar Biosciences, and use in inherited disease and pharmacogenomic testing. 16S rRNA & ITS microbial marker gene sequencing is set to grow the fastest, supported by expanding microbiome research, growing clinical gut microbiome testing, and the move to full-length long-read sequencing.
By platform, the 16S rRNA and amplicon sequencing market is segmented into long-read sequencing and short-read sequencing. Short-read sequencing is expected to hold the larger share in 2026, given its established role in 16S variable region studies, clinical amplicon panels, and viral genome surveillance, and the large installed base of short-read instruments in research and hospital laboratories. Long-read sequencing is set to grow at the higher CAGR, driven by full-length 16S and ITS sequencing, same-day workflows, and steady gains in long-read accuracy and throughput, with PacBio's Kinnex 16S kits and Oxford Nanopore's barcoding kits supporting this shift.
By application, the 16S rRNA and amplicon sequencing market is segmented into research, clinical diagnostics, public health & infectious disease surveillance, drug discovery & development, and agriculture, food & environmental testing. Research is expected to account for the largest share in 2026, reflecting heavy use of 16S and ITS sequencing in microbiome studies and of amplicon panels in genetic research at universities and institutes. Clinical diagnostics is set to grow at the highest CAGR, driven by rapid in-house amplicon oncology testing, new companion diagnostic approvals, and the spread of clinical microbiome testing. Drug discovery & development is also expected to grow strongly, supported by gene editing verification and biomarker studies.
By end user, the 16S rRNA and amplicon sequencing market is segmented into academic & research institutes, hospitals & clinical laboratories, pharmaceutical & biotechnology companies, public health laboratories, and agricultural & food companies. Academic & research institutes are expected to hold the largest share in 2026, as universities and research centers carry out much of the microbiome and genetic research that relies on amplicon methods. Hospitals & clinical laboratories are set to record the highest CAGR, driven by the move of NGS testing into hospital laboratories, rapid integrated sequencers, and growth in clinical microbiome testing.
In 2026, North America is expected to lead the global 16S rRNA and amplicon sequencing market, owing to strong funding for microbiome and genomic research, high use of clinical NGS, the availability of FDA-approved amplicon companion diagnostics, and the presence of leading suppliers such as Illumina, PacBio, Thermo Fisher Scientific, Pillar Biosciences, Zymo Research, and Integrated DNA Technologies. Viral surveillance by public health laboratories adds further demand in the U.S., and Canada contributes through microbiome research and public health genomics. Europe holds a significant share, supported by academic microbiome research, in-hospital clinical NGS, and the presence of QIAGEN and Oxford Nanopore Technologies; hospital laboratories often use CE-IVD panels, and the EU In Vitro Diagnostic Regulation raises the value of validated panels. The U.K., Germany, France, the Netherlands, and Italy are the leading European markets.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding microbiome research, wider cancer NGS testing, big crop and livestock genomics programs, and added public health sequencing capacity. China is expected to hold the largest share in the region, supported by its sizable sequencing services sector and farm genomics work, with strong growth also expected in Japan, South Korea, India, and Australia; in Australia, Microba Life Sciences sells clinical gut microbiome tests. Latin America and the Middle East & Africa hold smaller shares, with agricultural genotyping in Brazil and Argentina, pathogen surveillance and resistance testing in Africa supported by international public health programs, and clinical genomics investment in the Gulf.
A small number of sequencing platform makers and amplicon panel developers hold a significant part of the 16S rRNA and amplicon sequencing market, alongside specialist panel and reagent firms, microbiome workflow providers, bioinformatics companies, and sequencing service providers. Suppliers compete on panel content, accuracy, speed, cost per sample, regulatory approvals, and software. Recent activity includes the FDA approval of the Oncomine Dx Express Test in July 2025, Oxford Nanopore's Microbial Amplicon Barcoding Kit launch in September 2025, and Zymo Research's microbial community standards and benchmarked workflows shown at ASM Microbe 2026.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (Integrated DNA Technologies) (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Zymo Research Corporation (U.S.), and Pillar Biosciences, Inc. (U.S.).
The market covers the reagents, sequencers, software, and services that laboratories use to copy and then sequence chosen stretches of DNA or RNA. Amplicon methods use PCR to enrich target regions before sequencing, which keeps costs low, works with small amounts of input, and supports detection of low-frequency variants. Uses in scope include 16S rRNA gene and internal transcribed spacer (ITS) sequencing to profile bacteria and fungi, human gene panels for cancer hotspot mutations, inherited disease, and pharmacogenomics, tiled and targeted panels for viral genomes and drug resistance, genotyping for crop and livestock breeding and food checks, and confirmation of gene editing outcomes. Shotgun metagenomics, hybrid capture-based targeted sequencing, whole-genome and whole-exome sequencing, and PCR or qPCR assays without a sequencing readout are excluded.
Thermo Fisher Scientific's Oncomine Dx Express Test, approved in July 2025 by the Food and Drug Administration (FDA), is an amplicon test that covers 46 genes, runs on the Genexus Dx Integrated Sequencer, can return results within about a day, and serves as a companion diagnostic for sunvozertinib in EGFR exon 20 insertion non-small cell lung cancer and for solid tumor profiling. The FDA has also granted premarket approval to Pillar Biosciences' oncoReveal Dx Lung and Colon Cancer Assay. In microbiome testing, Microba Life Sciences reported a 78% rise in core testing volume to 22,418 tests in fiscal year 2026.
Market Dynamics
Microbiome research is a major driver of the 16S rRNA and amplicon sequencing market, since 16S sequencing remains the lowest-cost way to profile bacterial communities across thousands of human, animal, and environmental samples and is the standard method for cohort studies, clinical trials, and environmental surveys, with ITS sequencing used for fungi. Targeted amplicon panels add strong clinical demand, as they find actionable mutations in small tissue and cytology samples quickly and let hospital laboratories run NGS in-house. Public health laboratories use tiled amplicon sequencing, first scaled for SARS-CoV-2, for influenza, RSV, mpox, and other viruses, and targeted panels detect resistance mutations in HIV and tuberculosis. Low sequencing needs per sample and simple workflows also suit large studies and smaller laboratories.Shotgun metagenomics, hybrid capture panels, and whole-genome sequencing are becoming cheaper and provide wider information, such as strain-level and functional microbial data or copy number changes and new fusions, which pulls some work away from amplicon methods. PCR bias, primer mismatches, chimeras, and differences in gene copy number between organisms can distort results, and short-read sequencing of 16S variable regions often cannot separate closely related species. Microbiome workflows also lack common choices of variable regions, primers, extraction methods, and pipelines, which makes studies hard to compare, while panels must be redesigned as clinical biomarkers change and viruses mutate in primer binding sites.
Reading the complete 16S and ITS regions on long-read instruments is a significant opportunity, as reading the whole gene raises taxonomic resolution to species and sometimes strain level while keeping amplicon economics; Oxford Nanopore Technologies launched its Microbial Amplicon Barcoding Kit 24 V14 in September 2025 with a library ready about one hour after PCR. Rapid in-house clinical NGS, verification of CRISPR edits in cell and gene therapy manufacturing, and agricultural genotyping, food authenticity, and environmental DNA testing offer further openings. Key trends include the shift to full-length and long-read amplicon sequencing, automated sample-to-result workflows, and combined DNA and RNA or multi-pathogen panels.
Segment Analysis
The report analyzes the market by offering, target type, platform, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the 16S rRNA and amplicon sequencing market is segmented into kits & reagents (amplicon panels & primers, library preparation kits, and other reagents), instruments, software & bioinformatics, and services. Kits & reagents are expected to hold the largest share in 2026, because panels, primers, and library preparation kits are consumed in every experiment and clinical test, and a broad base of installed sequencers of both read types keeps demand recurring. Services are set to record the highest CAGR, as large microbiome studies are outsourced to sequencing providers, clinical microbiome and oncology testing services expand, and cell and gene therapy developers buy editing verification work. Software & bioinformatics is expected to grow strongly on the need for standard microbiome pipelines and automated clinical reports, while instruments benefit from the uptake of integrated benchtop sequencers in hospitals.
By target type, the 16S rRNA and amplicon sequencing market is segmented into human targeted gene panels, 16S rRNA & ITS microbial marker gene sequencing, pathogen genome & resistance amplicon sequencing, plant & animal genotyping amplicons, and other targets. In 2026, human targeted gene panels, which include oncology, inherited disease, and pharmacogenomic panels, are expected to lead, driven by wide use of amplicon oncology panels for treatment selection, FDA-approved amplicon tests from Thermo Fisher Scientific and Pillar Biosciences, and use in inherited disease and pharmacogenomic testing. 16S rRNA & ITS microbial marker gene sequencing is set to grow the fastest, supported by expanding microbiome research, growing clinical gut microbiome testing, and the move to full-length long-read sequencing.
By platform, the 16S rRNA and amplicon sequencing market is segmented into long-read sequencing and short-read sequencing. Short-read sequencing is expected to hold the larger share in 2026, given its established role in 16S variable region studies, clinical amplicon panels, and viral genome surveillance, and the large installed base of short-read instruments in research and hospital laboratories. Long-read sequencing is set to grow at the higher CAGR, driven by full-length 16S and ITS sequencing, same-day workflows, and steady gains in long-read accuracy and throughput, with PacBio's Kinnex 16S kits and Oxford Nanopore's barcoding kits supporting this shift.
By application, the 16S rRNA and amplicon sequencing market is segmented into research, clinical diagnostics, public health & infectious disease surveillance, drug discovery & development, and agriculture, food & environmental testing. Research is expected to account for the largest share in 2026, reflecting heavy use of 16S and ITS sequencing in microbiome studies and of amplicon panels in genetic research at universities and institutes. Clinical diagnostics is set to grow at the highest CAGR, driven by rapid in-house amplicon oncology testing, new companion diagnostic approvals, and the spread of clinical microbiome testing. Drug discovery & development is also expected to grow strongly, supported by gene editing verification and biomarker studies.
By end user, the 16S rRNA and amplicon sequencing market is segmented into academic & research institutes, hospitals & clinical laboratories, pharmaceutical & biotechnology companies, public health laboratories, and agricultural & food companies. Academic & research institutes are expected to hold the largest share in 2026, as universities and research centers carry out much of the microbiome and genetic research that relies on amplicon methods. Hospitals & clinical laboratories are set to record the highest CAGR, driven by the move of NGS testing into hospital laboratories, rapid integrated sequencers, and growth in clinical microbiome testing.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis of the 16S rRNA and amplicon sequencing market considers research funding, clinical NGS adoption, regulatory approvals, public health sequencing capacity, and agricultural genomics activity.In 2026, North America is expected to lead the global 16S rRNA and amplicon sequencing market, owing to strong funding for microbiome and genomic research, high use of clinical NGS, the availability of FDA-approved amplicon companion diagnostics, and the presence of leading suppliers such as Illumina, PacBio, Thermo Fisher Scientific, Pillar Biosciences, Zymo Research, and Integrated DNA Technologies. Viral surveillance by public health laboratories adds further demand in the U.S., and Canada contributes through microbiome research and public health genomics. Europe holds a significant share, supported by academic microbiome research, in-hospital clinical NGS, and the presence of QIAGEN and Oxford Nanopore Technologies; hospital laboratories often use CE-IVD panels, and the EU In Vitro Diagnostic Regulation raises the value of validated panels. The U.K., Germany, France, the Netherlands, and Italy are the leading European markets.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, driven by expanding microbiome research, wider cancer NGS testing, big crop and livestock genomics programs, and added public health sequencing capacity. China is expected to hold the largest share in the region, supported by its sizable sequencing services sector and farm genomics work, with strong growth also expected in Japan, South Korea, India, and Australia; in Australia, Microba Life Sciences sells clinical gut microbiome tests. Latin America and the Middle East & Africa hold smaller shares, with agricultural genotyping in Brazil and Argentina, pathogen surveillance and resistance testing in Africa supported by international public health programs, and clinical genomics investment in the Gulf.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.A small number of sequencing platform makers and amplicon panel developers hold a significant part of the 16S rRNA and amplicon sequencing market, alongside specialist panel and reagent firms, microbiome workflow providers, bioinformatics companies, and sequencing service providers. Suppliers compete on panel content, accuracy, speed, cost per sample, regulatory approvals, and software. Recent activity includes the FDA approval of the Oncomine Dx Express Test in July 2025, Oxford Nanopore's Microbial Amplicon Barcoding Kit launch in September 2025, and Zymo Research's microbial community standards and benchmarked workflows shown at ASM Microbe 2026.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (Integrated DNA Technologies) (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Zymo Research Corporation (U.S.), and Pillar Biosciences, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global 16S rRNA and amplicon sequencing market.
- Explains how microbiome research, clinical oncology panels, and pathogen surveillance are shaping demand for amplicon products and services.
- Assesses the impact of broader sequencing methods, PCR bias, and weak workflow standardization on amplicon demand.
- Identifies high-growth opportunities across offering, target type, platform, application, end user, and region.
- Tracks full-length 16S and ITS sequencing, rapid in-house clinical testing, and gene editing verification.
- Benchmarks leading companies by panel portfolios, platform coverage, workflow speed, regulatory approvals, and software.
- Supports product planning, partnering, regulatory strategy, and market entry decisions for platform makers, panel and reagent suppliers, service providers, and investors.
Key Questions Answered
- How big is the global 16S rRNA and amplicon sequencing market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will long-read, complete-gene 16S and ITS sequencing change microbiome research?
- Which offering, target type, platform, application, and end-user segments will grow the fastest?
- How are rapid amplicon-based companion diagnostics supporting in-house clinical NGS testing?
- How do amplicon methods compare with shotgun metagenomics and hybrid capture in cost and resolution?
- What role does amplicon sequencing play in viral surveillance and drug resistance testing?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and what strategies are they using to compete?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. 16S rRNA and Amplicon Sequencing Market, by Offering
6. 16S rRNA and Amplicon Sequencing Market, by Target Type
7. 16S rRNA and Amplicon Sequencing Market, by Platform
8. 16S rRNA and Amplicon Sequencing Market, by Application
9. 16S rRNA and Amplicon Sequencing Market, by End User
10. 16S rRNA and Amplicon Sequencing Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Danaher Corporation
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- Zymo Research Corporation
- Pillar Biosciences, Inc.
